Is the Pill as Good as the Shot?

For anyone who would rather swallow something than inject it, the question is simple: does the pill work as well? An indirect comparison of oral semaglutide 25 mg against injectable semaglutide 2.4 mg concludes they are comparable across every outcome examined.^[1] That conclusion is reasonable, and it means something narrower than it sounds.

Why similar results are expected

These are the same molecule. The obstacle with oral delivery has never been whether semaglutide works when swallowed — it is that peptides are destroyed in the stomach, which is why the oral formulation requires an absorption enhancer, an empty stomach, minimal water, and a thirty-minute wait.

The paper’s stated rationale is that the two formulations achieve comparable systemic exposure — similar drug levels in the blood. If that holds, a similar effect is the expected finding rather than a surprising one, and the analysis is confirming a prediction rather than discovering something.

Safety profiles were described as broadly comparable, and small numerical advantages appeared for each formulation on different endpoints.

What 'comparable' is actually claiming

Demonstrating equivalence requires deciding in advance how large a difference would matter, and then showing the interval sits entirely inside it. That boundary is called a non-inferiority margin, and it is chosen rather than discovered.

This analysis uses the FDA’s 5% threshold for clinical relevance in weight management, and the intervals do sit comfortably inside it. That is a legitimate anchor and it is a wide one — a five percentage point margin is roughly a third of what semaglutide achieves in total. The wider the margin, the easier equivalence is to claim.

Every equivalence claim contains a decision about how much difference would count.

So the defensible reading is this: on the evidence available, there is no demonstrated meaningful difference between the two formulations at these doses, judged against a threshold regulators consider reasonable. That is genuinely useful, and it is weaker than “they are the same.”

Two things not to confuse

• This is 25 mg oral, not 7 or 14 mg. Those lower strengths are the diabetes doses, and they are what a different trial compared against orforglipron — the first pill-versus-pill trial. A conclusion about 25 mg says nothing about 14.
• This is an indirect comparison, not a head-to-head. No trial has randomized people to the pill or the injection. The method, and how much weight it can carry, is in comparing trials that never met.

The practical differences that remain are not about efficacy. The tablet demands a daily routine — fasting, minimal water, no food for half an hour — that the weekly injection does not, and adherence to that routine is what determines whether the drug is absorbed at all. Which formulation suits someone depends more on that than on a one percentage point difference nobody could measure reliably.